COMP <GO>
VKTX vs UNH // FORWARD P/E MULTIPLE
Viking Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: VKTX 6
— UNH 8
▲ FORWARD P/E MULTIPLE LEADER: UNH
LAST: $27.28 (+1.56%) • MKT CAP: $3.38B
forward-pe
35.0x
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
forward-pe
17.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VKTX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VKTX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 44.00% | 88.57% | -44.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 11.47% | -46.47 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.25% | 6.48% | -14.73 | UNH | /fcf-yield <GO> |
| Operating Margin | 16.50% | 4.82% | +11.68 | VKTX | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 3.14% | +9.26 | VKTX | /net-margins <GO> |
| Revenue Growth (YoY) | 15.40% | 6.46% | +8.94 | VKTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 24.02 | 3.12 | +20.90 | VKTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.74% | -0.14 | VKTX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.0 | 56.0 | -8.07 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.33 | +0.58 | VKTX | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 35.0x | 17.1x | +17.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.38B | $364.66B | -$361.28B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VKTX REV | UNH REV | VKTX GROSS % | UNH GROSS % | VKTX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $447.57B | — | 88.7% | -$278.7M | $16.07B |
| FY 2024 | $0 | $400.28B | — | 88.3% | -$87.8M | $20.70B |
| FY 2023 | $0 | $371.62B | — | 89.6% | -$73.4M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VKTX // BETA 0.91
UNH // BETA 0.33